• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

    5/6/25 8:00:00 AM ET
    $LXRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LXRX alert in real time by email

    THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

    Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website. 

    About Lexicon Pharmaceuticals 

    Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, Lexicon's unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com. 

    For Investor and Media Inquiries: 

    Lisa DeFrancesco  

    Lexicon Pharmaceuticals, Inc. 

    [email protected] 



    Primary Logo

    Get the next $LXRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LXRX

    DatePrice TargetRatingAnalyst
    3/5/2025$2.00 → $1.00Outperform → Market Perform
    Leerink Partners
    6/17/2024$10.00Buy
    H.C. Wainwright
    4/30/2024$5.00Outperform
    Leerink Partners
    3/7/2023$3.00Hold
    Jefferies
    8/12/2022$10.00Overweight
    Piper Sandler
    More analyst ratings

    $LXRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

      Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for

      5/13/25 4:00:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

      THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company's website at https://investors.lexpharma.com/. About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through the Genome5000™ program, Lexicon's unique genomics target di

      5/6/25 4:30:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast wi

      5/6/25 8:00:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Lexicon Pharmaceuticals Inc.

      SC 13D/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      12/9/24 9:33:20 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

      SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      11/14/24 4:26:14 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Lexicon Pharmaceuticals Inc.

      SC 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      11/12/24 10:32:10 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    SEC Filings

    See more
    • Lexicon Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

      5/13/25 4:03:06 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Lexicon Pharmaceuticals Inc.

      SCHEDULE 13G/A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Subject)

      5/12/25 10:36:17 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Lexicon Pharmaceuticals Inc.

      DEFA14A - LEXICON PHARMACEUTICALS, INC. (0001062822) (Filer)

      4/22/25 7:09:58 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Financials

    Live finance-specific insights

    See more
    • Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

      Company had a strong start to 2025, emerging as an R&D-focused organization Exclusive license agreement with Novo Nordisk for LX9851 executed; IND-enabling studies on track for completion in 2025 Phase 2b PROGRESS study confirmed 10 mg pilavapadin as appropriate dose for advancement into Phase 3 development for diabetic peripheral neuropathic pain Conference call and webcast at 5:00 pm ET THE WOODLANDS, Texas, May 13, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months ended March 31, 2025, and provided an update on key corporate milestones and accomplishments. "We began 2025 delivering on three of our goals for

      5/13/25 4:00:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

      THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update. Participants can access the conference call live via webcast on the Events page of the Company's website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast wi

      5/6/25 8:00:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 pm ET  THE WOODLANDS, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), today reported financial results for the three months and year ended December 31, 2024, and provided an update on key corporate milestones and accomplishments.  "In 2024, Lexicon made progress on our Lead to Succeed strategy, resulting in a complete repositioning of the company to focus on advancing our R&D pipe

      3/6/25 4:00:00 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for INPEFA issued to LEXICON PHARMACEUTICALS INC

      Submission status for LEXICON PHARMACEUTICALS INC's drug INPEFA (ORIG-1) with active ingredient SOTAGLIFLOZIN has changed to 'Approval' on 05/26/2023. Application Category: NDA, Application Number: 216203, Application Classification: Type 1 - New Molecular Entity

      5/30/23 10:02:49 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lexicon Pharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Lexicon Pharma from Outperform to Market Perform and set a new price target of $1.00 from $2.00 previously

      3/5/25 7:37:06 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Lexicon Pharma with a new price target

      H.C. Wainwright initiated coverage of Lexicon Pharma with a rating of Buy and set a new price target of $10.00

      6/17/24 7:36:12 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Lexicon Pharma with a new price target

      Leerink Partners initiated coverage of Lexicon Pharma with a rating of Outperform and set a new price target of $5.00

      4/30/24 6:26:57 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Coats Lonnel bought $94,797 worth of shares (90,000 units at $1.05), increasing direct ownership by 11% to 914,359 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      11/17/23 4:55:09 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Coats Lonnel bought $10,100 worth of shares (10,000 units at $1.01), increasing direct ownership by 1% to 824,359 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      11/13/23 5:31:49 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Debbane Raymond bought $1,103,957 worth of shares (1,000,000 units at $1.10), increasing direct ownership by 293% to 1,340,847 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      10/12/23 4:01:18 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Swain Judith L converted options into 36,810 shares, increasing direct ownership by 76% to 85,174 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      5/13/25 5:52:13 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sullivan Diane E. converted options into 36,810 shares (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      5/13/25 5:51:31 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sobecki Christopher J converted options into 36,810 shares, increasing direct ownership by 22% to 203,865 units (SEC Form 4)

      4 - LEXICON PHARMACEUTICALS, INC. (0001062822) (Issuer)

      5/13/25 5:50:50 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LXRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Lexicon Appoints Scott Coiante as Chief Financial Officer

      THE WOODLANDS, Texas, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced the appointment of Scott Coiante as senior vice president and chief financial officer, effective today, January 2, 2025. Mr. Coiante is a senior finance executive with more than 35 years of experience in the life science and pharmaceutical industries. He joins Lexicon from Agile Therapeutics, where he served as the senior vice president, chief financial officer and treasurer of Agile Therapeutics Inc. from August 2023 to August 2024, as well as from 2011-2019. "I am pleased to join Lexicon at this pivotal moment for the company and eager to contribute to its

      1/2/25 8:00:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Appoints Ivan H. Cheung to Board of Directors

      THE WOODLANDS, Texas, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that Ivan H. Cheung has been elected to its Board of Directors. Mr. Cheung is a biopharmaceutical executive with more than 25 years of experience in the healthcare industry and a proven track record of shareholder value creation. He is currently the chief executive officer and a director of NextPoint Therapeutics, and he has served as senior advisor to TPG Growth – a growth investing platform within global asset manager TPG – since September 2023. "I am honored to join the Lexicon Board of Directors at this pivotal moment in the company's history, and to support its mis

      11/20/24 4:05:47 PM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director

      THE WOODLANDS, Texas, July 08, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that the Lexicon Board of Directors has appointed Mike Exton, Ph.D. as chief executive officer and director of Lexicon. Dr. Exton succeeds Lonnel Coats who, as previously announced, retired effective July 7, 2024. Dr. Exton most recently served as the global cardiometabolic therapeutic head at Novartis. "I am confident that Mike is the right person to serve as Lexicon's next chief executive officer at this critical time for the company," said Ray Debbane, chairman of Lexicon's board of directors. "He is an inspiring leader with a demonstrated track record of success, includi

      7/8/24 9:15:00 AM ET
      $LXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care